Kim BJ, Kwon SU, Park JH, et al. - In the present study, the researchers analyzed interactions between treatment and subgroups of the PICASSO trial (Prevention of Cardiovascular Events in Asian Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage) to identify patients who would benefit most from cilostazol. Patients with ischemic stroke with an earlier intracerebral hemorrhage or multiple microbleeds were randomized to treatment with cilostazol or aspirin and followed up for a mean 1.8 years. The data presented in this work showed a significant interaction between the treatment group and index of high risk for cerebral hemorrhage on hemorrhagic stroke among all 1,534 individuals recruited. In the cilostazol group, heart rate and high-density lipoprotein cholesterol levels were significantly higher than in the aspirin group at follow-up. For ischemic stroke patients with multiple cerebral microbleeds, cilostazol can be more beneficial and extensive before changes in white matter occur.